At the time of writing, Sarepta Therapeutics Inc [SRPT] stock is trading at $55.23, up 2.68%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SRPT shares have gain 8.23% over the last week, with a monthly amount drifted -24.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on April 11, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $115. Previously, H.C. Wainwright upgraded its rating to Neutral on April 02, 2025, and kept the price target unchanged to $75. On March 31, 2025, downgrade downgraded it’s rating to Sector Perform and revised its price target to $87 on the stock. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $136 on February 11, 2025. Needham reiterated its recommendation of a Buy and reduced its price target to $202 on November 27, 2024. H.C. Wainwright started tracking with a Sell rating for this stock on November 25, 2024, and assigned it a price target of $80. In a note dated November 07, 2024, Cantor Fitzgerald upgraded an Overweight rating on this stock and boosted its target price from $152 to $167.
For the past year, the stock price of Sarepta Therapeutics Inc fluctuated between $48.01 and $173.25. Currently, Wall Street analysts expect the stock to reach $186 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $55.23 at the most recent close of the market. An investor can expect a potential return of 236.77% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
According to Sarepta Therapeutics Inc [NASDAQ:SRPT], the company’s sales were 1.90B for trailing twelve months, which represents an 65.94% jump. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.2 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.87.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.32 points at the first support level, and at 51.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.63, and for the 2nd resistance point, it is at 58.02.
Ratios To Look Out For
It is important to note that Sarepta Therapeutics Inc [NASDAQ:SRPT] has a current ratio of 4.20. As well, the Quick Ratio is 3.18, while the Cash Ratio is 1.51. Considering the valuation of this stock, the price to sales ratio is 2.82, the price to book ratio is 3.50 and price to earnings (TTM) ratio is 23.17.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
